AssetMark Inc
BCAX icon

AssetMark Inc’s Bicara Therapeutics BCAX Stock Holding History

AssetMark Inc’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$465 Buy
+25
New +$626 ﹤0.01% 3428

Other funds holding BCAX

Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Private Trust Company
Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

AssetMark Inc's BCAX Position: Q3 2026 in Review

AssetMark Inc opened a new position in Bicara Therapeutics (BCAX) in Q3 2026: 25 shares worth $465. The stake represents ﹤0.01% of the portfolio and ranks #3428 among its holdings.

12 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • AssetMark Inc held 25 shares of Bicara Therapeutics worth $465 as of Q3 2026.
  • Bicara Therapeutics was a new AssetMark Inc position in Q3 2026.
  • Bicara Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3428 holding.
  • 12 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.